Cellectar Biosciences Inc represents values of innovation, dedication, and commitment to advancing the field of precision medicine. The company's corporate philosophy focuses on developing groundbreaking targeted therapeutic solutions to improve patients' lives. With a strong emphasis on research and development, Cellectar Biosciences Inc aims to enhance the understanding and treatment of cancer and other diseases. By leveraging its proprietary technology platforms, the company aims to provide unique and effective therapies that target specific molecular features of diseases. Cellectar Biosciences Inc is driven by a mission to revolutionize healthcare through the development of novel and personalized treatments, ensuring a bright future for patients and the medical community.

Cellectar Biosciences Inc is primarily present in the United States of America.

Cellectar Biosciences Inc, a leading biopharmaceutical company, has achieved several significant milestones. Firstly, they developed and advanced their novel PDC platform technology, enabling targeted cancer treatments. Additionally, Cellectar Biosciences successfully completed multiple clinical trials for their PDC therapeutic candidates, demonstrating promising efficacy and safety profiles. Moreover, they secured important strategic collaborations with renowned academic institutions and established partnerships with key pharmaceutical companies. Cellectar Biosciences continues to expand their pipeline and advance their PDC platform, aiming to revolutionize cancer treatment and improve patient outcomes.

Cellectar Biosciences Inc, a clinical-stage biopharmaceutical company, was founded in 2002 with its headquarters in Madison, Wisconsin, USA. The company focuses on the development and commercialization of innovative targeted therapeutic agents for the treatment of cancer. Cellectar Biosciences utilizes its proprietary phospholipid drug conjugate (PDC) delivery platform to design and develop a diverse pipeline of precision oncology therapies. This platform allows for the selective delivery of potent cytotoxic agents to cancer cells, while sparing healthy tissues. With a strong commitment to oncology advancements, Cellectar Biosciences Inc has positioned itself as a leader in targeted cancer therapies.

The main competitors of Cellectar Biosciences Inc in the market are Aytu Bioscience, Curis, and Endocyte.

Cellectar Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

Cellectar Biosciences Inc is a biopharmaceutical company that focuses on developing novel treatments for cancer. The company's business model revolves around the design, development, and commercialization of innovative therapeutics based on its proprietary phospholipid drug conjugate (PDC) delivery platform. Cellectar Biosciences aims to leverage this technology to create targeted, tumor-specific treatments that have the potential to improve patient outcomes and transform the way cancer is treated. By utilizing its PDC platform, the company aims to address the limitations of traditional cancer therapies and provide more effective and personalized treatment options for patients.

Cellectar Biosciences KGV ir -0,33.

Cellectar Biosciences KUV ir 0.

AlleAktien kvalitātes vērtējums Cellectar Biosciences ir 6/10.

Pašreiz nevar aprēķināt apgrozījumu Cellectar Biosciences.

gaidāmā Cellectar Biosciences peļņa ir -64,72 milj. USD.

Cellectar Biosciences is a clinically oriented biopharmaceutical company focused on the discovery, development, and commercialization of innovative cancer diagnostics and therapies. The company is currently developing a new generation of cancer drugs, including radioactive therapeutics and light-activated therapeutics (LITs), based on specific target structures. The company's focus is on developing drugs targeted at specific cancer cells. These drugs can recognize and bind to specific target molecules on the surface of cancer cells. Once the drug is bound to the target molecule, it releases a therapeutic effect. Such an effect can be the destruction of the cancer cell itself or the targeted delivery of a medication. The company uses a platform technology called "phospholipid ether (PLE)" to transport the active ingredient into the cancer tissue. The PLE technology is based on the fact that cancer cells often have more PLE molecules on their surface than healthy cells. Cellectar Biosciences' drugs can be used to specifically kill cancer cells or transport medications specifically to cancer cells. Cellectar Biosciences' cancer diagnostics products include "CLR 131" and "CLR 125". CLR 131 is a radioactive therapy that can be used as both a diagnostic and therapeutic agent. It is used to treat solid tumors that do not respond to topical treatment and is also suitable for preventing tumor cell spread. On the other hand, CLR 125 is a non-radioactive diagnostic agent used for the detection of various tumors. The company is also working on the development of LITs based on luminescence. This technology enables the targeted killing of cancer cells by using specific target molecules on the surface of cancer cells and light. The LIT technology can be used for cancer diagnosis and targeted drug delivery. Cellectar Biosciences has an effective business model that focuses exclusively on the development of cancer drugs. The company collaborates with partners in the pharmaceutical industry to bring its products to market. By focusing on a specific niche, the company has a high barrier to entry and can develop innovative products that provide real value in cancer treatment.

Cellectar Biosciences izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Cellectar Biosciences vai uzņēmums nedod dividendes.

Cellectar Biosciences ISIN ir US15117F5008.

Cellectar Biosciences WKN ir A2NB71.

Cellectar Biosciences simbols ir CLRB.

Pēdējo 12 mēnešu laikā Cellectar Biosciences maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Cellectar Biosciences plāno maksāt dividendes 0 USD apmērā.

Cellectar Biosciences pašreizējā dividendu rentabilitāte ir .

Cellectar Biosciences maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Cellectar Biosciences pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Cellectar Biosciences tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Cellectar Biosciences apmērā 0 USD, kas tika izmaksāta 19.11.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 19.11.2024..

Pēdējās dividendes izmaksa notika 19.11.2024..

Gadā 2023, Cellectar Biosciences izmaksāja 0 USD dividendes.

Cellectar Biosciences dividendes tiek izmaksātas USD.